Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.42 |
| ▸ | KAT8 | Q9H7Z6 | 5/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | F2R | P25116 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5548746 | 0.81 | DRD2 (0.49) | DRD2KDM4DAAK1CCR6IRAK4 | |
| SCHEMBL5545235 | 0.81 | DRD2 (0.49) | DRD2KDM4DAAK1CCR6IRAK4 | |
| SCHEMBL5548342 | 0.81 | DRD2 (0.49) | DRD2KDM4DAAK1CCR6IRAK4 | |
| SCHEMBL5545283 | 0.80 | DRD2 (0.49) | DRD2KDM4DAAK1JAK1JAK3 | |
| SCHEMBL5548799 | 0.79 | DRD2 (0.55) | DRD2KDM4DAAK1BTKKCNA3 | |
| SCHEMBL5543293 | 0.79 | DRD2 (0.55) | DRD2KDM4DAAK1BTKKCNA3 | |
| SCHEMBL5548711 | 0.76 | MAOB (0.52) | DRD2KAT8BTKKCNA3 | |
| SCHEMBL5548715 | 0.76 | MAOB (0.52) | DRD2KAT8BTKKCNA3 | |
| SCHEMBL5543212 | 0.76 | MAOB (0.52) | DRD2KAT8BTKKCNA3 | |
| SCHEMBL1938116 | 0.75 | CCR6 (0.53) | DRD2KDM4DCCR6IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | claimed |
| US-7230002-B2 | Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2007-06-12 | — | — | US | disclosed |
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | DPP4, DPP3, DPP7 | DRD2 3398/4885KDM4D 635/4885KAT8 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.